A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.

Andrew J NunnPatrick P J PhillipsSarah K MeredithChen-Yuan ChiangFrancesca ConradieDoljinsuren DalaiArmand van DeunPhan-Thuong DatNgoc LanIqbal MasterTesfamarium MebrahtuDaniel MeressaRonelle MoodliarNosipho NgubaneKaren SandersStephen Bertel SquireGabriela TorreaBazarragchaa TsogtI D Rusennull null

Published in: The New England journal of medicine (2019)

In persons with rifampin-resistant tuberculosis that was susceptible to fluoroquinolones and aminoglycosides, a short regimen was noninferior to a long regimen with respect to the primary efficacy outcome and was similar to the long regimen in terms of safety. (Funded by the U.S. Agency for International Development and others; Current Controlled Trials number, ISRCTN78372190; ClinicalTrials.gov number, NCT02409290.).

Keyphrases

mycobacterium tuberculosis
clinical trial
pulmonary tuberculosis
hiv aids
study protocol
emergency department
phase ii
hepatitis c virus
human immunodeficiency virus
drug administration